Breno Bittencourt de Brito
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Breno Bittencourt de Brito has a total of 40 co-authors. Here are the top co-authors by number of shared publications:
- Fabrício Freire de Melo
Instituto Multidisciplinar em Saúde, Universidade Federal da Bahia, Vitória da Conquista 45029-094, Bahia, Brazil.
10 shared publications Filipe Antônio França da Silva
Instituto Multidisciplinar em Saúde, Universidade Federal da Bahia, Vitória da Conquista 45029-094, Bahia, Brazil
5 shared publicationsMaria Luísa Cordeiro Santos
Instituto Multidisciplinar em Saúde, Universidade Federal da Bahia, Vitória da Conquista 45029-094, Bahia, Brazil
5 shared publications- Filipe Antônio França da Silva
Instituto Multidisciplinar em Saúde, Universidade Federal da Bahia, Bahia, Brazil
2 shared publications Mariana Miranda Sampaio
Instituto Multidisciplinar em Saúde, Universidade Federal da Bahia, Vitória da Conquista 45029-094, Bahia, Brazil
2 shared publications- Márcio Vasconcelos Oliveira
Universidade Federal da Bahia, Brasil
2 shared publications
Latest Publications
- 30 June 2021
- Published by Taylor & Francis in Expert Review of Vaccines
- Vol. 20 (8) , 989-999
Vaccine development against Helicobacter pylori: from ideal antigens to the current landscape
Introduction: The interest of the world scientific community for an effective vaccine against Helicobacter pylori infection arises from its high prevalence and association with many diseases. Moreover, with an immunological response that is not always effective for the eradication of the bacteria and an increasing antibiotic resistance in the treatment of this infection, the search for a vaccine and new therapeutic modalities to control this infection is urgent. Areas covered: We bring an overview of the infection worldwide, discussing its prevalence, increasing resistance to antibiotics used in its therapy, in addition to the response of the immune system to the infection registered so far. Moreover, we address the most used antigens and their respective immunological responses expected or registered up to now. Finally, we address the trials and their partial results in development for such vaccines. Expert opinion: Although several studies for the development of an effective vaccine against this pathogen are taking place, many are still in the preclinical phase or even without updated information. In this sense, taking into account the high prevalence and association with important comorbidities, the interest of the pharmaceutical industry in developing an effective vaccine against this pathogen is questioned.
- 30 June 2021
- Published by Taylor & Francis in Expert Review of Vaccines
- Vol. 20 (8) , 989-999
Vaccine development against Helicobacter pylori: from ideal antigens to the current landscape
Introduction: The interest of the world scientific community for an effective vaccine against Helicobacter pylori infection arises from its high prevalence and association with many diseases. Moreover, with an immunological response that is not always effective for the eradication of the bacteria and an increasing antibiotic resistance in the treatment of this infection, the search for a vaccine and new therapeutic modalities to control this infection is urgent. Areas covered: We bring an overview of the infection worldwide, discussing its prevalence, increasing resistance to antibiotics used in its therapy, in addition to the response of the immune system to the infection registered so far. Moreover, we address the most used antigens and their respective immunological responses expected or registered up to now. Finally, we address the trials and their partial results in development for such vaccines. Expert opinion: Although several studies for the development of an effective vaccine against this pathogen are taking place, many are still in the preclinical phase or even without updated information. In this sense, taking into account the high prevalence and association with important comorbidities, the interest of the pharmaceutical industry in developing an effective vaccine against this pathogen is questioned.
- 1 September 2020
- Published by Elsevier in Travel Medicine and Infectious Disease
- Vol. 37, 101862
Coinfection by SARS-CoV-2 and dengue virus in a dual viral circulation setting
- 1 September 2020
- Published by Elsevier in Travel Medicine and Infectious Disease
- Vol. 37, 101862
Coinfection by SARS-CoV-2 and dengue virus in a dual viral circulation setting
- Open Access
- 28 July 2020
- Published by Baishideng Publishing Group Inc. in World Journal of Gastroenterology
- Vol. 26 (28) , 4076-4093
Helicobacter pylori infection: Beyond gastric manifestations
Helicobacter pylori infection: Beyond gastric manifestations
- 28 July 2020
- Published by Baishideng Publishing Group Inc. in World Journal of Gastroenterology
- Vol. 26 (28) , 4076-4093
Open AccessHelicobacter pylori infection: Beyond gastric manifestations
Helicobacter pylori infection: Beyond gastric manifestations
- Open Access
- 2 July 2020
- Published by Scientific Archives
- Vol. 1 (2)
Gastric Cancer: A Brief Review, from Risk Factors to Treatment
- 2 July 2020
- Published by Scientific Archives
- Vol. 1 (2)
Open AccessGastric Cancer: A Brief Review, from Risk Factors to Treatment
- Open Access
- 24 May 2020
- Published by Baishideng Publishing Group Inc. in World Journal of Clinical Oncology
- Vol. 11 (5) , 250-259
Immunotherapy – new perspective in lung cancer
Immunotherapy – new perspective in lung cancer
- 24 May 2020
- Published by Baishideng Publishing Group Inc. in World Journal of Clinical Oncology
- Vol. 11 (5) , 250-259
Open AccessImmunotherapy – new perspective in lung cancer
Immunotherapy – new perspective in lung cancer
- Open Access
- 28 April 2020
- Published by Baishideng Publishing Group Inc. in World Journal of Meta-Analysis
- Vol. 8 (2) , 54-66
Probiotics in inflammatory bowel disease: Does it work?
Probiotics in inflammatory bowel disease: Does it work?
- 28 April 2020
- Published by Baishideng Publishing Group Inc. in World Journal of Meta-Analysis
- Vol. 8 (2) , 54-66
Open AccessProbiotics in inflammatory bowel disease: Does it work?
Probiotics in inflammatory bowel disease: Does it work?
- Open Access
- 24 April 2020
- Published by Baishideng Publishing Group Inc. in World Journal of Clinical Oncology
- Vol. 11 (4) , 190-204
Nephrotoxicity in cancer treatment: An overview
Nephrotoxicity in cancer treatment: An overview
- 24 April 2020
- Published by Baishideng Publishing Group Inc. in World Journal of Clinical Oncology
- Vol. 11 (4) , 190-204
Open AccessNephrotoxicity in cancer treatment: An overview
Nephrotoxicity in cancer treatment: An overview
- Open Access
- 8 November 2019
- Published by Wiley in Helicobacter
- Vol. 25 (1) , e12667
Interleukin‐27 is abrogated in gastric cancer, but highly expressed in other Helicobacter pylori‐associated gastroduodenal diseases
Background: IL‐27 has dual roles in the immune response either stimulating Th1 or inhibiting Th17 cells. Because there is a particular link of IL‐23/Th17 axis in the development of cancer and IL‐27 has been considered a potential treatment for cancer, we evaluated the gastric and serum concentrations of IL‐27 in two mutually exclusive Helicobacter pylori‐associated diseases, gastric cancer (GC) and duodenal ulcer (DU).Material and Methods: We prospectively studied 110 H pylori‐positive patients and 40 healthy blood donors. Serum and gastric concentrations of IL‐27 and cytokines of the Th1/Th17 cells were assessed by ELISA.Results: IL‐27 was not detected in GC patients, but the cytokine concentration was very high in the patients with DU. IL‐27 was also detected in the gastritis patients and in the H pylori‐positive blood donors. IL27RA mRNA expression in peripheral blood mononuclear cells, evaluated by rt‐PCR, was stimulated by H pylori strains. The cytokine concentration positively correlated with the Th1 and negatively with Th17 cell representative cytokine levels. Gastric IL‐27 concentrations were positively correlated with increased degree of mononuclear and polymorphonuclear cells on the antral gastric mucosa of DU patients in consonance with the DU gastritis pattern. IL‐12p70 and IFN‐γ gastric concentrations were significantly higher in DU than in GC. Conversely, gastric concentrations of Th17 cell‐associated cytokines (IL‐1β, IL‐6, IL‐17A, IL‐23, and TGF‐β) were significantly higher in GC than in DU patients.Conclusion: Although H pylori infection is able to elicit IL‐27 and IL‐27Rα secretion, DU and GC have diametrically opposed cytokine patterns.
- 8 November 2019
- Published by Wiley in Helicobacter
- Vol. 25 (1) , e12667
Open AccessInterleukin‐27 is abrogated in gastric cancer, but highly expressed in other Helicobacter pylori‐associated gastroduodenal diseases
Background: IL‐27 has dual roles in the immune response either stimulating Th1 or inhibiting Th17 cells. Because there is a particular link of IL‐23/Th17 axis in the development of cancer and IL‐27 has been considered a potential treatment for cancer, we evaluated the gastric and serum concentrations of IL‐27 in two mutually exclusive Helicobacter pylori‐associated diseases, gastric cancer (GC) and duodenal ulcer (DU).Material and Methods: We prospectively studied 110 H pylori‐positive patients and 40 healthy blood donors. Serum and gastric concentrations of IL‐27 and cytokines of the Th1/Th17 cells were assessed by ELISA.Results: IL‐27 was not detected in GC patients, but the cytokine concentration was very high in the patients with DU. IL‐27 was also detected in the gastritis patients and in the H pylori‐positive blood donors. IL27RA mRNA expression in peripheral blood mononuclear cells, evaluated by rt‐PCR, was stimulated by H pylori strains. The cytokine concentration positively correlated with the Th1 and negatively with Th17 cell representative cytokine levels. Gastric IL‐27 concentrations were positively correlated with increased degree of mononuclear and polymorphonuclear cells on the antral gastric mucosa of DU patients in consonance with the DU gastritis pattern. IL‐12p70 and IFN‐γ gastric concentrations were significantly higher in DU than in GC. Conversely, gastric concentrations of Th17 cell‐associated cytokines (IL‐1β, IL‐6, IL‐17A, IL‐23, and TGF‐β) were significantly higher in GC than in DU patients.Conclusion: Although H pylori infection is able to elicit IL‐27 and IL‐27Rα secretion, DU and GC have diametrically opposed cytokine patterns.
- Top Cited PapersOpen Access
- 7 October 2019
- Published by Baishideng Publishing Group Inc. in World Journal of Gastroenterology
- Vol. 25 (37) , 5578-5589
Pathogenesis and clinical management of Helicobacter pylori gastric infection
Helicobacter pylori (H. pylori) is a gram-negative bacterium that infects approximately 4.4 billion individuals worldwide. However, its prevalence varies among different geographic areas, and is influenced by several factors. The infection can be acquired by means of oral-oral or fecal-oral transmission, and the pathogen possesses various mechanisms that improve its capacity of mobility, adherence and manipulation of the gastric microenvironment, making possible the colonization of an organ with a highly acidic lumen. In addition, H. pylori presents a large variety of virulence factors that improve its pathogenicity, of which we highlight cytotoxin associated antigen A, vacuolating cytotoxin, duodenal ulcer promoting gene A protein, outer inflammatory protein and gamma-glutamyl transpeptidase. The host immune system, mainly by means of a Th1-polarized response, also plays a crucial role in the infection course. Although most H. pylori-positive individuals remain asymptomatic, the infection predisposes the development of various clinical conditions as peptic ulcers, gastric adenocarcinomas and mucosa-associated lymphoid tissue lymphomas. Invasive and non-invasive diagnostic methods, each of them with their related advantages and limitations, have been applied in H. pylori detection. Moreover, bacterial resistance to antimicrobial therapy is a major challenge in the treatment of this infection, and new therapy alternatives are being tested to improve H. pylori eradication. Last but not least, the development of effective vaccines against H. pylori infection have been the aim of several research studies.
- 7 October 2019
- Published by Baishideng Publishing Group Inc. in World Journal of Gastroenterology
- Vol. 25 (37) , 5578-5589
Top Cited PapersOpen AccessPathogenesis and clinical management of Helicobacter pylori gastric infection
Helicobacter pylori (H. pylori) is a gram-negative bacterium that infects approximately 4.4 billion individuals worldwide. However, its prevalence varies among different geographic areas, and is influenced by several factors. The infection can be acquired by means of oral-oral or fecal-oral transmission, and the pathogen possesses various mechanisms that improve its capacity of mobility, adherence and manipulation of the gastric microenvironment, making possible the colonization of an organ with a highly acidic lumen. In addition, H. pylori presents a large variety of virulence factors that improve its pathogenicity, of which we highlight cytotoxin associated antigen A, vacuolating cytotoxin, duodenal ulcer promoting gene A protein, outer inflammatory protein and gamma-glutamyl transpeptidase. The host immune system, mainly by means of a Th1-polarized response, also plays a crucial role in the infection course. Although most H. pylori-positive individuals remain asymptomatic, the infection predisposes the development of various clinical conditions as peptic ulcers, gastric adenocarcinomas and mucosa-associated lymphoid tissue lymphomas. Invasive and non-invasive diagnostic methods, each of them with their related advantages and limitations, have been applied in H. pylori detection. Moreover, bacterial resistance to antimicrobial therapy is a major challenge in the treatment of this infection, and new therapy alternatives are being tested to improve H. pylori eradication. Last but not least, the development of effective vaccines against H. pylori infection have been the aim of several research studies.
- Open Access
- 14 September 2018
- Published by Baishideng Publishing Group Inc. in World Journal of Clinical Oncology
- Vol. 9 (5) , 83-89
Role of polymorphisms in genes that encode cytokines and Helicobacter pylori virulence factors in gastric carcinogenesis
Role of polymorphisms in genes that encode cytokines and Helicobacter pylori virulence factors in gastric carcinogenesis
- 14 September 2018
- Published by Baishideng Publishing Group Inc. in World Journal of Clinical Oncology
- Vol. 9 (5) , 83-89
Open AccessRole of polymorphisms in genes that encode cytokines and Helicobacter pylori virulence factors in gastric carcinogenesis
Role of polymorphisms in genes that encode cytokines and Helicobacter pylori virulence factors in gastric carcinogenesis